

Special Issue

Genetics in Inherited Retinal Diseases

Message from the Guest Editors

With the first approved gene therapy for an inherited retinal disease (IRD), the genetics underlying these blinding conditions have received considerable attention. Together with technological advances, this new focus helps to gain momentum towards improved access to molecular genetic diagnostics and further academic work on existing knowledge gaps. This Special Issue aims to provide a snapshot of some of the current IRDs in focus of translational efforts. Contributions might shed light on the genetic heterogeneity of mutations found in a specific disease gene, explore genotype-phenotype correlations, characterise model systems reflecting the genetic pathology, diagnostic biomarkers, pathophysiological mechanisms, and novel therapeutic approaches. To progress in the knowledge of such intricate issues, contributions by experts in the field in the form of research papers and critical reviews are called for.

Guest Editors

Prof. Dr. M. Dominik Fischer

1. Oxford Eye Hospital, Oxford University Hospital NHS Foundation Trust, Oxford, UK
2. Nuffield Laboratory of Ophthalmology, NDCN, University of Oxford, Oxford, UK

Prof. Dr. Susan Downes

1. Oxford Eye Hospital, Oxford University Hospital NHS Foundation Trust, Oxford, UK
2. Nuffield Laboratory of Ophthalmology, NDCN, University of Oxford, Oxford, UK

Deadline for manuscript submissions

closed (15 November 2023)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/86167

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2
(Genetics (clinical))